Navigation Links
TPI to Develop New Formulation for Flagship Product Gingko Mihuan
Date:11/3/2011

CHENGDU, China, Nov. 3, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI, or the "Company"), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API) today announced the formulation expansion program for its flagship product Gingko Mihuan Oral Liquid (GMOL, SFDA certification number: H20013079; patent number: 20061007800225). GMOL, the proprietary prescription medicine for TPI with averaged annual revenue of $22 million, is used nationwide in China to treat brain ischemia and infarction, coronary heart diseases, memory dysfunction and other neurological disorders.

Major components in the Gingko extracts are flavonoids and terpenoids. Flavonoids consist of ginkgoflavone glycoside which are potent antioxidant that reduce capillary fragility which was frequently observed in cardiovascular disorders. Terpenoids consist of ginkgolides and bilobalide that inhibit platelet activating factor (PAF) which in consequence reduce the blood viscosity (Ma et al. J Nat Med. 2011; Maerz et al. Biosci Rep. 2011). GMOL also contains extracts from Gastrodia elata that were used for neurological symptoms such as epilepsy, headaches, dizziness and memory dysfunction (Tsai et al. J Ethnopharmacol. 2011; Kim et al. Molecules 2011).

The current oral liquid formulation for GMOL shows efficient absorption rate after intake, especially for elderly patients who are also afflicted with gastro-intestinal ailments. The new capsule form is more convenient to carry when travel and easy to use. In addition, the cost of production and packaging material prices for liquid formulation has been rising during the recent years. The new capsule formulation will reduce the overall cost of sales by 70% while extending the expiration period to 3 years from the current 2 years for oral liquid form. The new capsule formulation is expected to support the revenue growth of GMOL at approximately 30% year over year and improving the gross margin of GMOL products to 75% or higher. TPI will also apply for patent protection for the new capsule formulation. The research and development cost is estimated at $1-2 million. TPI expects to begin production of the new capsule formulation in approximately 12-15 months.

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and active pharmaceutical ingredients (API). TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

For more information about TPI and GMOL, please visit:  http://www.tianyinpharma.com and www.sfda.gov.cn (Chinese version).

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharma.com, or email ir@tianyinpharma.com    
Tel: +86-28-8551-6696 (Chengdu, China)
+86-134-3655-0011 (China)
Address:
Tianyin Pharmaceutical
23rd Floor, Unionsun Yangkuo Plaza      
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China


'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Newly Launched US BioDesign to Provide OEM Development/Manufacturing Services to Medical Device Customers
2. JDRF and the Helmsley Charitable Trust Form a Collaboration to Accelerate Innovative Type 1 Diabetes Research and Development
3. AgonOx Partners with MedImmune for Development of OX40 Agonists in Cancer Therapy
4. ZONARE Medical Systems Announces Appointment of PJ Ryland as Vice President of Business Development & Corporate Accounts
5. CMC Biologics Announces Agreement With Daiichi Sankyo Company to Develop and Manufacture Antibodies
6. Laparoscopic Surgeons Develop Fluorescent Light Technique to Improve Pancreatic Cancer Detection
7. Covance Receives Good Laboratory Practice Certification for Its Early Development Facility in Shanghai, China
8. 50 Pharma Companies Worldwide Now Use Codexis In Process Development
9. Colorcon and BASF Announce Collaboration to Develop Film Coating Applications Using Kollicoat® Smartseal 30 D
10. FDA Awards Precision Antibody Contract to Develop Monoclonal Antibodies for Influenza Vaccine Potency Assays
11. VaxyGen Manufacturing Services LLC Announces Exclusive License and Collaborative Agreement with Georgia State University Research Foundation to Commercialize Novel Biological Process Development Patent, Expertise & Know-How
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , May 26, 2016 A ... growth is the emergence of new treatments. Cardax, a ... for osteoarthritis treatment. The therapy is expected to fulfil ... Research UK is conducting studies to develop new treatments ... where the genes involved in osteoarthritis are being investigated, ...
(Date:5/26/2016)... 2016 Since its commercial introduction ... essential life science tool for conducting genetic studies in ... reveals in its new report that the industry sits ... powered by a range of new applications in the ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the ...
(Date:5/25/2016)... und GERMANTOWN, Maryland , May ... mit Therawis bedient dringenden ... QIAGEN N.V. (NASDAQ: QGEN ... eine Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH ... Onkologie eingegangen zu sein. Ein erstes Projekt wird ...
Breaking Medicine Technology:
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... The ... industry, today released ten predictions on the future of wellness, travel, spa and beauty ... top travel, spa and beauty companies to leading economists and researchers - to forecast ...
(Date:5/31/2016)... ... ... The Orthopaedic Research and Education Foundation (OREF) is pleased to announce the following ... term as president in March, succeeding John J. Callaghan, MD, who remains on the ... Kyle, MD, will serve as chair, corporate development, succeeding Thomas P. Schmalzried, MD, in ...
(Date:5/31/2016)... ... ... a recent interview on The Greenburgh Report radio show hosted by Greenburgh, NY Town ... leading medical insurance advocate Adria Goldman Gross discussed several eye-opening issues that have combined ... the interview with Mr. Feiner that aired on May 7, 2016, Ms. Gross, the ...
(Date:5/31/2016)... ... May 31, 2016 , ... To meet a ... the healthcare industry, The University of Scranton is adding a Certificate in Health ... a career in rapidly growing field of healthcare information. , Healthcare organizations ...
(Date:5/30/2016)... ... May 30, 2016 , ... "This plugin ... said Christina Austin - CEO of Pixel Film Studios. , TransPack Volume ... Pro X. Choose from abstract transitions to more simple wipes with blur & ...
Breaking Medicine News(10 mins):